Long-Term Enoxaparin Use in Clinical Contexts

Cancer-Associated Venous Thromboembolism

The National Comprehensive Cancer Network (NCCN) guidelines designate dalteparin as the preferred low molecular weight heparin (LMWH) for cancer patients with proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) for the first 6 months, with enoxaparin as an acceptable alternative 1
Enoxaparin 1 mg/kg subcutaneously every 12 hours is listed as an acceptable monotherapy option for cancer patients with VTE, although long-term management with this dosing has not been tested in cancer patients 1
Systematic reviews have shown that LMWH, such as dalteparin, has similar or lower recurrence rates compared to warfarin for 3-6 months, with similar bleeding rates 2
A large cancer trial demonstrated significantly lower recurrence rates with dalteparin (4% vs 11% for DVT) and no significant difference in bleeding compared to warfarin 2

A prospective cohort study showed that long-term LMWH, such as dalteparin, is effective and safe for non-cancer patients with VTE, with recurrence rates of 2.2% 2
LMWH may be particularly useful for patients in whom international normalized ratio (INR) control is difficult 2
Cost-effectiveness analysis showed that LMWH is relatively expensive, with an incremental cost-effectiveness ratio of $149,864/quality-adjusted life-year, unless daily drug cost is less than $18 per day 2

The TIMI-11B trial showed that extended enoxaparin therapy (43 days) did not establish a role for long-term use of LMWH in patients with unstable angina/non-ST-elevation myocardial infarction (NSTEMI) 3
The FRISC-II trial demonstrated a significant reduction in events at 30 days, but not at 3 months, with dalteparin versus placebo in patients with acute coronary syndromes 3, 4
Benefits of prolonged administration were limited to medically managed patients and those with elevated troponin at baseline 4

For cancer-associated VTE, the recommended dose of enoxaparin is 1 mg/kg subcutaneously every 12 hours 1
Monitoring of hemoglobin, hematocrit, and platelet count should be performed at least every 2-3 days for the first 14 days, then every 2 weeks thereafter 1, 5
For patients with severe renal impairment (CrCl <30 mL/min), the dose of enoxaparin should be reduced to 1 mg/kg once daily 6

Enoxaparin has a delayed clearance in renal dysfunction due to its longer half-life compared to unfractionated heparin (UFH) 6
Major bleeding occurs in 0.1-0.7% of patients, with clinically relevant non-major bleeding in 2.6-3.3% 6
Intracranial hemorrhage risk increases significantly in elderly patients (>75 years) when combined with fibrinolytics 6
A platelet count decline >50% from baseline should raise suspicion for heparin-induced thrombocytopenia (HIT) 5